What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
His primary areas of investigation include Lung cancer, Cancer research, Epidermal growth factor receptor, Internal medicine and Adenocarcinoma.
His Lung cancer study focuses on T790M in particular.
His research in Cancer research intersects with topics in Mutation, Gene, Gene mutation, Exon and Tumor suppressor gene.
His Epidermal growth factor receptor research includes elements of Gene duplication, KRAS and Pharmacology.
His Internal medicine research is multidisciplinary, relying on both Gastroenterology, Surgery and Oncology.
His biological study spans a wide range of topics, including Immunohistochemistry, Lymph node, Pathology and Respiratory disease, Lung.
His most cited work include:
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling (3639 citations)
- International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma (3017 citations)
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial (2971 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Lung cancer, Internal medicine, Oncology, Cancer research and Epidermal growth factor receptor.
His Lung cancer research is multidisciplinary, incorporating elements of Cancer and Adenocarcinoma.
His work deals with themes such as Gastroenterology and Surgery, which intersect with Internal medicine.
Tetsuya Mitsudomi has included themes like Stage, Clinical trial, Cisplatin and Hazard ratio in his Oncology study.
In his study, Osimertinib is inextricably linked to T790M, which falls within the broad field of Cancer research.
The various areas that Tetsuya Mitsudomi examines in his Epidermal growth factor receptor study include Tyrosine kinase, Molecular biology and Tyrosine-kinase inhibitor.
He most often published in these fields:
- Lung cancer (60.07%)
- Internal medicine (40.77%)
- Oncology (32.95%)
What were the highlights of his more recent work (between 2015-2021)?
- Lung cancer (60.07%)
- Internal medicine (40.77%)
- Oncology (32.95%)
In recent papers he was focusing on the following fields of study:
Tetsuya Mitsudomi mainly focuses on Lung cancer, Internal medicine, Oncology, Cancer research and Osimertinib.
The study incorporates disciplines such as Lung and Adenocarcinoma in addition to Lung cancer.
His study looks at the intersection of Adenocarcinoma and topics like Pathology with Metastasis.
Within one scientific family, Tetsuya Mitsudomi focuses on topics pertaining to Gastroenterology under Internal medicine, and may sometimes address concerns connected to Carcinoembryonic antigen.
His Oncology study combines topics from a wide range of disciplines, such as Stage and Chemotherapy.
His Cancer research study incorporates themes from Acquired resistance, Epidermal growth factor receptor, Mutation, Afatinib and Exon.
Between 2015 and 2021, his most popular works were:
- Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial (384 citations)
- Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study (320 citations)
- Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial (209 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
The scientist’s investigation covers issues in Lung cancer, Cancer research, Internal medicine, Osimertinib and T790M.
His Lung cancer research integrates issues from Cancer, Adenocarcinoma and Immunology.
Tetsuya Mitsudomi interconnects Erlotinib, Epidermal growth factor receptor, Afatinib, Mutation and Pathology in the investigation of issues within Cancer research.
His Internal medicine study frequently draws connections to other fields, such as Oncology.
His Oncology research is multidisciplinary, incorporating elements of Chemotherapy and Hazard ratio.
His work in Osimertinib addresses subjects such as Epithelial–mesenchymal transition, which are connected to disciplines such as CD44 and Gene knockdown.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
